RxDoctor Payments DataLook up a doctor →

William Shergy, MD

Rheumatology · Huntsville, ALNPI 1073531307

Payments from drug & device makers

$453,125in general payments, 2019–2025

Across 1,185 payments — averaging $382.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$126K
  • Amgen$94K
  • AbbVie$83K
  • Gilead$65K
  • E.r. Squibb & Sons, L.L.C.$24K
  • Bristol Myers Squibb$19K
  • plus $42K from 33 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer83$126,374
Amgen(2 entities)230$93,832
AbbVie298$83,021
Gilead25$65,123
E.r. Squibb & Sons, L.L.C.51$23,963
Bristol Myers Squibb36$18,897
Janssen Scientific Affairs, LLC20$15,789
Janssen Research & Development, LLC7$6,962
Johnson & Johnson(2 entities)63$6,528
Teva Pharmaceuticals USA, Inc.9$3,728
Novartis103$2,248
Sanofi US Services Inc.1$1,745
UCB, Inc.91$1,133
GSK49$1,005
AstraZeneca(2 entities)31$677
Sanofi7$529
Mallinckrodt Hospital Products Inc.5$292
Genentech USA, Inc.23$291
Boehringer Ingelheim7$159
Radius Health, Inc.9$145
Regeneron Healthcare Solutions, Inc.8$121
Fresenius Kabi USA, LLC5$85
Lilly USA, LLC4$77
Mylan Institutional Inc.2$50
Mallinckrodt Enterprises LLC2$49
Aurinia Pharma U.S., Inc.2$41
Sanofi-aventis U.S. LLC1$33
Actelion Pharmaceuticals US, Inc.2$32
Pacira Pharmaceuticals Incorporated1$23
Kiniksa Pharmaceuticals International, PLC1$21
Sobi, Inc1$21
Octapharma USA, Inc.1$21
Kyowa Kirin, Inc.1$20
Celltrion USA Inc.1$18
Scilex Pharmaceuticals Inc.1$17
Tonix Medicines, Inc.1$16
Kiniksa Pharmaceuticals, Ltd.1$14
Merck1$13
Medexus Pharma, Inc.1$12

How this compares

$453,125 in reported general payments places this provider in the 90th percentile of 90 rheumatology providers in Alabama.

See all rheumatology providers in Alabama →

Medicare billing

Part B allowed, 2024
$2,902,644
Medicare patients
935
Services billed
176,594

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other rheumatology in Huntsville

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →